

Antimicrobial Susceptibility Test Results for Gram-positive isolates recovered from all sites: 2025

Organism Name	Antibiotics in common use (1st line reporting)										
	Number tested	Ampicillin/ amoxicillin	Penicillin	Meth/Flucloxacillin	Erythromycin	Clindamycin #	Gentamicin	Nitrofurantoin ^d	Trimethoprim ^d	Trimethoprim+sulfamethoxazole	Vancomycin #
<i>S. aureus</i> (not MRSA)	558		20	100 ^a	91	92	94			99	
MRSA *	36		0	0	81	89	94			97	
<i>S. saprophyticus</i>	24	100		100				100	96	96	
<i>Enterococcus faecalis</i> /spp ^b	123	99						98			100
<i>Streptococcus pneumoniae</i> *	10	100			80	80				100	
<i>Enterococcus faecium</i> (inc. 6 x VRE)	8										
<i>Streptococcus</i> GrpA	0										

Reserved
Ciprofloxacin #
98

Topical
Chloramphenicol
96

Antimicrobial Susceptibility Test Results for Gram-negative isolates recovered from all sites: 2025

Organism Name	Antibiotics in common use (1st line reporting)									
	Number tested	Ampicillin/ amoxicillin	Amoxicillin-Clavulanate	Cefuroxime IV	Cefalexin ^d	Gentamicin	Nitrofurantoin ^d	Trimethoprim ^d	Trimethoprim+sulfamethoxazole	Tetracycline
<i>Escherichia coli</i> (inc. 33 ESBL)	656	65	71		94	97	100	83	91	
ESKCM group	47	0	0		0	98		78	87	
<i>Klebsiella oxytoca</i> *	26	0	100		100	100		100	100	
<i>Klebsiella pneumoniae</i>	68	0	88		94	94		86	91	

Reserved (2nd line reporting)			
Ceftriaxone	Ciprofloxacin #	Meropenem #	Piperacillin-Tazobactam \$
95	89	100	99
87	98	100	91
100	100	100	100
97	98	100	100

<i>Proteus mirabilis</i>	38	89	97		97	95		83	88	
<i>Haemophilus influenzae</i>	45	49	82	73					60	100
<i>Pseudomonas aeruginosa</i>	40									
<i>ESCM group: Enterobacter spp, Serratia marcescens, Klebsiella aerogenes, Citrobacter spp, Morganella morganii</i>										

97	95	100	100
	90	97	96

* Tested on 10- 30 isolates

^a *S. aureus* susceptible to methicillin/flucloxacillin denotes susceptibility to cefazolin and amoxicillin-clavulanate

^b Enterococcus species are intrinsically resistant to cephalosporins

^c Includes Intermediate (Susceptible, Increased Exposure) results

^d Treatment of uncomplicated urinary tract infections only

Use requires patient-specific Infectious Diseases/Clinical Microbiology approval (document in clinical notes) unless following Te Whata Kura national antimicrobial guidelines.

\$ Use requires patient-specific Infectious Diseases/Clinical Microbiology/Respiratory Specialist approval (document in clinical notes) unless following Te Whata Kura national antimicrobial guidelines.

No data or not tested
Colour Interpretation
≥ 90% Susceptible
70 - 89% Susceptible
< 70% Susceptible

